[Combined therapy ICS/LABA--new therapeutical trends in patients with asthma and chronic obstructive pulmonary disease].
Clinical study results showed that combined therapy--inhaled glucocorticosteroid (ICS) plus long-acting 32-agonists (LABA)--allows for better control of asthma and chronic obstructive pulmonary disease, reducing the number of exacerbations. There are strong scientific evidence for the use of both drugs in one inhaler, because they exhibit complementary and synergy of clinical activity at the molecular level. SMART therapy, ie one inhaler used for chronic and on-demand allows for better control of the disease than the use of on-demand short-acting beta2-agonists. Analysis of the results of several multicenter clinical trial failed to demonstrate the impact of LABA on ICS and reduce the value of the natural forced expiratory volume in one second. Nevertheless, the results of almost all studies have shown benefits in such indicators as the frequency of exacerbations, improved quality of life and other exponents of health.
Chazan
Ryszarda
R
D000280:Administration, Inhalation; D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage*; D001249:Asthma / Q000188:drug therapy*; D004338:Drug Combinations; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy*; D011788:Quality of Life
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D004338:Drug Combinations; D005938:Glucocorticoids